WDB coco Co

WDB coco Co OCF/Debt

The Operating Cash Flow to Debt Ratio of WDB coco Co (7079.T) as of Oct 26, 2026 is 709.58 %. In the previous year, Operating Cash Flow to Debt Ratio was 3,704.05 % — a change of -80.84% (lower).

OCF/Debt

709.58 %

YoY

-80.84%

Last updated:

Operating Cash Flow to Debt Ratio of WDB coco Co is 2026 709.58 % . Operating Cash Flow to Debt Ratio of WDB coco Co was 2025 3,704.05 % . It decreases by -80.84% lower compared to the previous year.

The WDB coco Co OCF/Debt history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

OCF/Debt
Date
OCF/Debt
Jan 1, 2019
8,032.54 JPY
Jan 1, 2020
4,960.14 JPY
Jan 1, 2021
1,471.86 JPY
Jan 1, 2022
2,231.08 JPY
Jan 1, 2023
2,127.76 JPY
Jan 1, 2024
2,846.93 JPY
Jan 1, 2025
3,704.05 JPY
Jan 1, 2026
709.58 JPY
The WDB coco Co OCF/Debt history
YEAROCF/DebtYoY
709.58 %-80.84%
3,704.05 %+30.11%
2,846.93 %+33.80%
2,127.76 %-4.63%
2,231.08 %+51.58%
1,471.86 %-70.33%
4,960.14 %-38.25%
8,032.54 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

WDB coco Co Stock analysis

What does WDB coco Co do? WDB coco Co., Ltd. generates revenue through safety information management services, document support services, development support services, and clinical development support services. The company acts as an agent and support provider for drug development, offering input, evaluation, drafting, and reporting for safety information. Document support services cover QC, translation, and creation of CTD applications for PMDA approval. Development support includes survey form management, document filing, and call center operations. Clinical development support handles clinical trial-related tasks. The primary customers are pharmaceutical companies requiring regulatory compliance and efficient drug development processes. The company serves pharmaceutical firms needing assistance with safety data management, regulatory document preparation, and clinical trial support. Its services are tailored to meet PMDA requirements for marketing approval, particularly through CTD applications. The document support service specifically targets the creation and translation of materials for PMDA submissions. Development support services are utilized by clients managing clinical surveys and trial documentation. Clinical development support is contracted by pharmaceutical companies conducting clinical trials. WDB coco Co., Ltd. provides end-to-end support for drug development lifecycle, from safety data handling to clinical trial management. Its safety information management service is integral for regulatory submissions, while document support ensures compliance with PMDA standards. Development and clinical support services streamline trial operations, reducing time-to-market for pharmaceutical products. The company’s revenue streams are directly tied to the demand for regulatory and clinical support in the pharmaceutical industry. WDB coco Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about WDB coco Co stock

Operating Cash Flow to Debt Ratio of WDB coco Co is 709.58 % in 2026.

Operating Cash Flow to Debt Ratio of WDB coco Co changed from 3,704.05 % to 709.58 %, representing a -80.84% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Operating Cash Flow to Debt Ratio WDB coco Co since 2006 – with annual values, charts, and detailed analysis.

OCF/Debt measures what percentage of total debt can be covered by annual operating cash flow. Higher ratios indicate stronger debt repayment capacity.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Operating Cash Flow to Debt Ratio's WDB coco Co with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Leverage — WDB coco Co

All Key Metrics — WDB coco Co